why choose us

300×250 Ad Slot

Research Article: Efficacy, Safety, and Durability of Brolucizumab: An -Month Post-Marketing Surveillance Analysis

Date Published: 2023-09-20

Introduction:
Brolucizumab (Beovu ® ) is a low molecular weight humanized antibody fragment developed by Novartis (Cambridge, MA) as a vascular endothelial growth factor (VEGF) inhibitor. Registered Phase III clinical trials HAWK (NCT) and HARRIER (NCT) showed brolucizumab was associated with gains in visual acuity (VA) that were statistically noninferior to aflibercept for treatment-naïve patients with active choroidal neovascularization secondary to neovascular age-related macular degeneration (nvAMD). Brolucizumab received…

Read more

300×250 Ad Slot